ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $619,365 | -38.2% | 55,449 | +18.3% | 0.00% | 0.0% |
| Q2 2023 | $1,002,654 | +7.1% | 46,853 | +102.3% | 0.00% | 0.0% |
| Q1 2023 | $936,510 | -13.8% | 23,158 | -0.8% | 0.00% | -50.0% |
| Q4 2022 | $1,086,195 | -99.9% | 23,349 | -11.4% | 0.00% | 0.0% |
| Q3 2022 | $1,367,345,000 | +366.3% | 26,361 | +325.0% | 0.00% | – |
| Q2 2022 | $293,216,000 | -51.2% | 6,203 | -26.5% | 0.00% | -100.0% |
| Q1 2022 | $600,973,000 | -67.5% | 8,443 | -65.9% | 0.00% | -66.7% |
| Q4 2021 | $1,850,431,000 | +72.9% | 24,745 | +31.4% | 0.00% | +50.0% |
| Q3 2021 | $1,069,960,000 | +223.8% | 18,834 | +150.9% | 0.00% | – |
| Q2 2021 | $330,427,000 | -14.4% | 7,508 | -4.0% | 0.00% | -100.0% |
| Q1 2021 | $385,880,000 | +204.9% | 7,824 | +160.3% | 0.00% | – |
| Q4 2020 | $126,553,000 | -42.9% | 3,006 | -38.0% | 0.00% | – |
| Q3 2020 | $221,804,000 | -81.2% | 4,845 | -79.4% | 0.00% | -100.0% |
| Q2 2020 | $1,180,889,000 | -31.7% | 23,519 | -30.1% | 0.00% | -50.0% |
| Q1 2020 | $1,729,334,000 | +650.9% | 33,625 | +802.0% | 0.00% | – |
| Q4 2019 | $230,316,000 | +42.4% | 3,728 | +38.5% | 0.00% | – |
| Q3 2019 | $161,735,000 | +2.2% | 2,692 | +43.5% | 0.00% | – |
| Q2 2019 | $158,297,000 | -52.6% | 1,876 | -46.4% | 0.00% | -100.0% |
| Q1 2019 | $334,129,000 | +78518.6% | 3,498 | +58200.0% | 0.00% | – |
| Q4 2018 | $425,000 | -99.1% | 6 | -98.9% | 0.00% | – |
| Q3 2018 | $47,345,000 | -95.0% | 554 | -93.2% | 0.00% | -100.0% |
| Q2 2018 | $948,873,000 | -6.8% | 8,187 | -34.9% | 0.00% | 0.0% |
| Q1 2018 | $1,017,929,000 | -15.1% | 12,581 | -38.4% | 0.00% | 0.0% |
| Q4 2017 | $1,198,715,000 | +243.5% | 20,428 | +174.0% | 0.00% | +100.0% |
| Q3 2017 | $348,941,000 | +120.0% | 7,456 | +69.1% | 0.00% | – |
| Q2 2017 | $158,636,000 | +90.3% | 4,409 | +62.9% | 0.00% | – |
| Q1 2017 | $83,376,000 | -16.4% | 2,707 | -9.0% | 0.00% | – |
| Q4 2016 | $99,696,000 | +68.9% | 2,976 | +34.2% | 0.00% | – |
| Q3 2016 | $59,021,000 | -39.4% | 2,218 | -49.8% | 0.00% | – |
| Q2 2016 | $97,417,000 | +60.8% | 4,418 | +114.2% | 0.00% | – |
| Q1 2016 | $60,590,000 | -51.6% | 2,063 | -45.6% | 0.00% | – |
| Q4 2015 | $125,278,000 | -3.2% | 3,794 | +5.9% | 0.00% | – |
| Q3 2015 | $129,417,000 | +116.0% | 3,581 | +168.8% | 0.00% | – |
| Q2 2015 | $59,927,000 | +686.0% | 1,332 | +434.9% | 0.00% | – |
| Q1 2015 | $7,624,000 | -76.2% | 249 | -69.3% | 0.00% | – |
| Q3 2014 | $32,091,000 | +2092.0% | 811 | +2285.3% | 0.00% | – |
| Q2 2014 | $1,464,000 | – | 34 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |